Nerve agent antidotes
View Patent ↗The present invention includes compositions that are useful in treating, ameliorating, or preventing nerve agent poisoning. The present invention also includes methods of preventing, treating or ameliorating nerve agent poisoning in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition of the invention. The present invention also includes methods of preventing, treating or ameliorating a seizure induced by a disease or disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition of the invention. The present invention also comprises a kit comprising compositions of the invention.
1. A composition comprising at least one GABAA receptor agonist, at least one NMDA antagonist, and at least one additional therapeutic for the treatment or amelioration of nerve agent poisoning;
wherein the at least one GABAA receptor agonist is a benzodiazepine;
wherein the at least one NMDA antagonist is ketamine; and
wherein the at least one additional therapeutic is selected from the group consisting of an anticonvulsant and an antiepileptic.
2. The composition of claim 1 , wherein the at least one GABAA receptor agonist is diazepam.
3. The composition of claim 1 , wherein the at least one GABAA receptor agonist is midazolam.
4. The composition of claim 1 , wherein the at least one anticonvulsant is valproate.
5. The composition of claim 1 , wherein the at least one anticonvulsant is brivaracetam.
6. A composition comprising at least one GABAA receptor agonist, at least one NMDA antagonist, and at least one additional therapeutic for the treatment or amelioration of a seizure induced by a disease or disorder;
wherein the at least one GABAA receptor agonist is a benzodiazepine;
wherein the at least one NMDA antagonist is ketamine; and
wherein the at least one additional therapeutic is selected from the group consisting of an anticonvulsant and an antiepileptic.
7. The composition of claim 6 , wherein the disease or disorder is selected from the group consisting of an acute seizure, status epilepticus (SE), epilepsy, stroke, traumatic brain injury, and cardiac arrest, drug use, drug withdrawal, alcohol withdrawal, a bacterial, fungal, or viral infection, a tumor, a metabolic encephalopathy associated with hypo- or hyperglycemia, hypo- or hypernatremia, acidosis, alkalosis, hepatic, uremic hypoxic-ischemic or other encephalopathy, an autoimmune or inflammatory process, adegenerative brain disease, and a gene defect.
8. The composition of claim 6 , wherein the at least one GABAA receptor agonist is diazepam.
9. The composition of claim 6 , wherein the at least one GABAA receptor agonist is midazolam.
10. The composition of claim 6 , wherein the at least one anticonvulsant is valproate.
11. The composition of claim 6 , wherein the at least one anticonvulsant is brivaracetam.
12. A kit comprising a composition comprising a therapeutically effective amount of at least one GABAA receptor agonist, at least one NMDA antagonist, and at least one additional therapeutic;
wherein the at least one GABAA receptor agonist is a benzodiazepine;
wherein the at least one NMDA antagonist is ketamine; and
wherein the at least one additional therapeutic is selected from the group consisting of an anticonvulsant and an antiepileptic.
13. The kit of claim 12 , wherein the kit further comprises a device for administrating the composition.
14. The kit of claim 13 , wherein the device is an autoinjector.
15. The composition of claim 1 , wherein the at least one GABAA receptor agonist is a benzodiazepine selected from the group consisting of diazepam, and midazolam, and the at least one additional therapeutic is selected from the group consisting of valproate and brivaracetam.
16. The composition of claim 6 , wherein the at least one GABAA receptor agonist is a benzodiazepine selected from the group consisting of diazepam, and midazolam, and the at least one additional therapeutic is selected from the group consisting of valproate and brivaracetam.
17. The kit of claim 12 , wherein the at least one GABAA receptor agonist is a benzodiazepine selected from the group consisting of diazepam, and midazolam, and the at least one additional therapeutic is selected from the group consisting of valproate and brivaracetam.